http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010168058-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_efe83f78bb71f24864d9b19bee417132 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-739 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P19-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H3-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-715 |
| filingDate | 2006-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_99e7ebab6a89de523d952ddd042b30b1 |
| publicationDate | 2010-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2010168058-A1 |
| titleOfInvention | Novel antagonists of the toll-like receptor 4 |
| abstract | The present invention relates to a novel antagonist of the Toll-like receptor 4 (TLR-4). More specifically, the present invention relates to a lipopolysaccharide (LPS) isolated from the bacterium Bartonella quintana as a novel antagonist of the Toll-like receptor 4 (TLR-4). Further, the present invention relates to the use of said natural antagonist for the treatment of an autoimmune or inflammatory disease in a mammal and specifically for the treatment of rheumatoid arthritis (RA). Furthermore, the present invention relates to pharmaceutical compositions comprising a lipopolysaccharide (LPS) isolated from the bacterium Bartonella quintana. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10639346-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2013324471-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9889176-B2 |
| priorityDate | 2006-10-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 574.